In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Cytori Therapeutics Inc (NASDAQ: CYTX), with a price target of $5. The company’s shares closed yesterday at $0.43, close to its 52-week low of $0.32.
Kolbert wrote:
“Our valuation for Cytori is based on success with the current therapeutics pipeline with probability of success factors weighted in each therapeutic area. These forecasts feed into our valuation metrics, of free cash flow to the firm (FCFF), discounted EPS (dEPS) and sum- of-the-parts (SOP) models.”
According to TipRanks.com, Kolbert has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.6% and a 36.6% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Coherus Biosciences, and Can-Fite BioPharma.
Cytori Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.70 and a one-year low of $0.32. Currently, Cytori Therapeutics Inc has an average volume of 744.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytori Therapeutics, Inc. is a late stage cell therapy company which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.
